熱門資訊> 正文

Travere Therapeutics任命Bradley Campbell为首席执行官，取代Eric Dube

2026-09-22 04:24

Travere Therapeutics (TVTX) has appointed Bradley Campbell as chief executive officer, effective December 1, 2026, the compnay said on Monday.
The announcement came after Eric Dube said he will step down as CEO and president to focus on his health and family.
Campbell was the former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical.
Source: Press Release

More on Travere Therapeutics

Travere Therapeutics: Valuation Suggests A Buy
Travere Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again)
Travere signals potential for more than $3B in peak annual FILSPARI sales as FSGS launch exceeds expectations
Travere Therapeutics Non-GAAP EPS of -$0.10 misses by $0.42, revenue of $161.4M beats by $4.13M

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。